-
Product Insights
NewNet Present Value Model: Verrica Pharmaceuticals Inc’s Ycanth
Empower your strategies with our Net Present Value Model: Verrica Pharmaceuticals Inc's Ycanth report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Genital Warts (Condylomata Acuminata) – Drugs In Development, 2023
Global Markets Direct’s, ‘Genital Warts (Condylomata Acuminata) - Drugs In Development, 2023’, provides an overview of the Genital Warts (Condylomata Acuminata) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Genital Warts (Condylomata Acuminata), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2023’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Human Papillomavirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Human Papillomavirus Infections - Drugs In Development, 2023’, provides an overview of the Human Papillomavirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KIO-301 in Retinitis Pigmentosa (Retinitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KIO-301 in Retinitis Pigmentosa (Retinitis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.KIO-301 in Retinitis Pigmentosa (Retinitis) Drug Details:KIO-301 (B-203) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ESK-001 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ESK-001 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ESK-001 in Systemic Lupus Erythematosus Drug Details: ESK-001 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cantharidin in Molluscum Contagiosum
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cantharidin in Molluscum Contagiosum report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cantharidin in Molluscum Contagiosum Drug Details: Cantharidin (VP-102) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene-Modified Cell Therapy to Target HPV-16 E6 for Cervical Cancer in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene-Modified Cell Therapy to Target HPV-16 E6 for Cervical Cancer in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Gene-Modified Cell Therapy To...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cantharidin in Genital Warts (Condylomata Acuminata)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cantharidin in Genital Warts (Condylomata Acuminata) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cantharidin in Genital Warts (Condylomata Acuminata) Drug Details: Cantharidin (Ycanth)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LTX-315 in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LTX-315 in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LTX-315 in Basal Cell Carcinoma (Basal Cell Epithelioma) Drug...